89 related articles for article (PubMed ID: 8867646)
1. The modulation of granulomatous tissue and tumour angiogenesis by diclofenac in combination with hyaluronan (HYAL EX-0001).
Freemantle C; Alam CA; Brown JR; Seed MP; Willoughby DA
Int J Tissue React; 1995; 17(4):157-66. PubMed ID: 8867646
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan.
Seed MP; Brown JR; Freemantle CN; Papworth JL; Colville-Nash PR; Willis D; Somerville KW; Asculai S; Willoughby DA
Cancer Res; 1997 May; 57(9):1625-9. PubMed ID: 9134996
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action.
Moore AR; Willoughby DA
Int J Tissue React; 1995; 17(4):153-6. PubMed ID: 8867645
[TBL] [Abstract][Full Text] [Related]
4. Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac in combination with hyaluronan in mice.
Alam CA; Seed MP; Willoughby DA
J Pharm Pharmacol; 1995 May; 47(5):407-11. PubMed ID: 7494192
[TBL] [Abstract][Full Text] [Related]
5. Tetrahydro-derivatives of cortisone promote granulomatous tissue angiogenesis in vivo on topical application in hyaluronan.
Alam C; Colville-Nash P; Seed MP; Willoughby D
Angiogenesis; 1998; 1(2):185-191. PubMed ID: 14517384
[TBL] [Abstract][Full Text] [Related]
6. The pharmacological modulation of angiogenesis in chronic granulomatous inflammation.
Colville-Nash PR; Alam CA; Appleton I; Brown JR; Seed MP; Willoughby DA
J Pharmacol Exp Ther; 1995 Sep; 274(3):1463-72. PubMed ID: 7562523
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways.
Slevin M; Krupinski J; Gaffney J; Matou S; West D; Delisser H; Savani RC; Kumar S
Matrix Biol; 2007 Jan; 26(1):58-68. PubMed ID: 17055233
[TBL] [Abstract][Full Text] [Related]
8. The effect of hyaluronan on the in vitro deposition of diclofenac within the skin.
Brown MB; Marriott C; Martin GP
Int J Tissue React; 1995; 17(4):133-40. PubMed ID: 8867643
[TBL] [Abstract][Full Text] [Related]
9. Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment of actinic keratoses.
Rivers JK
Skin Therapy Lett; 2004 Jan; 9(1):1-3. PubMed ID: 14716439
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
Lincoln DT; Singal PK; Al-Banaw A
Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592
[TBL] [Abstract][Full Text] [Related]
11. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses.
Rivers JK; McLean DI
Arch Dermatol; 1997 Oct; 133(10):1239-42. PubMed ID: 9382562
[TBL] [Abstract][Full Text] [Related]
12. Topical diclofenac: new preparation. Moderate efficacy in actinic keratosis.
Prescrire Int; 2004 Aug; 13(72):138-9. PubMed ID: 15532138
[TBL] [Abstract][Full Text] [Related]
13. Brain hyaluronan binding protein inhibits tumor growth.
Gao F; Cao ML; Wang L
Chin Med J (Engl); 2004 Jul; 117(7):1072-8. PubMed ID: 15265385
[TBL] [Abstract][Full Text] [Related]
14. Diclofenac/hyaluronic acid.
Peters DC; Foster RH
Drugs Aging; 1999 Apr; 14(4):313-9; discussion 320-1. PubMed ID: 10319244
[TBL] [Abstract][Full Text] [Related]
15. Modes of action of diclofenac 3%/hyaluronic acid 2.5% in the treatment of actinic keratosis.
Maltusch A; Röwert-Huber J; Matthies C; Lange-Asschenfeldt S; Stockfleth E
J Dtsch Dermatol Ges; 2011 Dec; 9(12):1011-7. PubMed ID: 21585654
[TBL] [Abstract][Full Text] [Related]
16. Tumour vascularisation: a druggable target.
Bishop-Bailey D
Curr Opin Pharmacol; 2009 Apr; 9(2):96-101. PubMed ID: 19056315
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-12 has no effect on vascular density, perfusion, hypoxia and proliferation of an implanted human squamous cell carcinoma xenograft tumour despite up-regulation of ICAM-1.
van Herpen CM; Bussink J; van der Kogel AJ; Peeters WJ; van der Voort R; van Schijndel A; de Wilde PC; Adema GJ; de Mulder PH
Anticancer Res; 2005; 25(2A):1015-21. PubMed ID: 15868941
[TBL] [Abstract][Full Text] [Related]
18. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis.
Noguera-Troise I; Daly C; Papadopoulos NJ; Coetzee S; Boland P; Gale NW; Lin HC; Yancopoulos GD; Thurston G
Nature; 2006 Dec; 444(7122):1032-7. PubMed ID: 17183313
[TBL] [Abstract][Full Text] [Related]
19. Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies.
Pirard D; Vereecken P; Mélot C; Heenen M
Arch Dermatol Res; 2005 Nov; 297(5):185-9. PubMed ID: 16235081
[TBL] [Abstract][Full Text] [Related]
20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
